TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy
Brief Summary: The purpose of this study is to assess whether adherence to NVUGIB guidelines is improved with implementation of a national, tailored multifaceted intervention. Outcomes include adherence rates to two key endoscopic and pharmacological therapy guidelines together (primary), or adherence to these individually as well as to other recommendations (secondary). Patient outcomes and economic data are also assessed (tertiary).


Options:
A: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention
B: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: safety program; Assigned to Arm(s): N/A
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Barrier assessment / interactive educational intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Barrier assessment / interactive educational intervention; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy
Brief Summary: The purpose of this study is to assess whether adherence to NVUGIB guidelines is improved with implementation of a national, tailored multifaceted intervention. Outcomes include adherence rates to two key endoscopic and pharmacological therapy guidelines together (primary), or adherence to these individually as well as to other recommendations (secondary). Patient outcomes and economic data are also assessed (tertiary).


Options:
A: Arm Label: Intervention group; Type: N/A; Interventions: Behavioral: reminders | Arm Label: current practice group; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: reminders; Assigned to Arm(s): Intervention group
B: Arm Label: SA, AJ, PC; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Decision Support: Accountable Justification, Behavioral: Audit and Feedback: Peer Comparison, Behavioral: CDS Order Sets: Suggested Alternatives | Arm Label: SA, AJ; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Decision Support: Accountable Justification, Behavioral: CDS Order Sets: Suggested Alternatives | Arm Label: SA, PC; Type: EXPERIMENTAL; Interventions: Behavioral: Audit and Feedback: Peer Comparison, Behavioral: CDS Order Sets: Suggested Alternatives | Arm Label: AJ, PC; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Decision Support: Accountable Justification, Behavioral: Audit and Feedback: Peer Comparison | Arm Label: Peer Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Audit and Feedback: Peer Comparison | Arm Label: Suggested Alternatives; Type: EXPERIMENTAL; Interventions: Behavioral: CDS Order Sets: Suggested Alternatives | Arm Label: Accountable Justification; Type: EXPERIMENTAL; Interventions: Behavioral: Clinical Decision Support: Accountable Justification | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinical Decision Support: Accountable Justification; Assigned to Arm(s): AJ, PC, Accountable Justification, SA, AJ, SA, AJ, PC | Intervention Type: BEHAVIORAL; Name: Audit and Feedback: Peer Comparison; Assigned to Arm(s): AJ, PC, Peer Comparison, SA, AJ, PC, SA, PC | Intervention Type: BEHAVIORAL; Name: CDS Order Sets: Suggested Alternatives; Assigned to Arm(s): SA, AJ, SA, AJ, PC, SA, PC, Suggested Alternatives
C: Intervention Type: BEHAVIORAL; Name: Evidence summaries endorsed by local opinion leaders; Assigned to Arm(s): N/A
D: Arm Label: Educational intervention; Type: EXPERIMENTAL; Interventions: Other: Educational intervention | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational intervention; Assigned to Arm(s): Educational intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Brief Summary: It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
C: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
D: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Brief Summary: It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Cerebrolysin + donepezil; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + donepezil | Arm Label: Cerebrolysin + placebo; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin + placebo | Arm Label: Donepezil + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Donepezil + placebo | Intervention Type: DRUG; Name: Cerebrolysin + donepezil; Assigned to Arm(s): Cerebrolysin + donepezil | Intervention Type: DRUG; Name: Cerebrolysin + placebo; Assigned to Arm(s): Cerebrolysin + placebo | Intervention Type: DRUG; Name: Donepezil + placebo; Assigned to Arm(s): Donepezil + placebo
D: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Brief Summary: It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.


Options:
A: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
B: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Brief Summary: It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.


Options:
A: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: local interarterial recombinant tissue plasminogen activator | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous (IV) rt-PA | Intervention Type: DRUG; Name: local interarterial recombinant tissue plasminogen activator; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: intravenous (IV) rt-PA; Assigned to Arm(s): 2
C: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: IV tPA; Type: EXPERIMENTAL; Interventions: Drug: Tissue Plasminogen Activator (Alteplase) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tissue Plasminogen Activator (Alteplase); Assigned to Arm(s): IV tPA | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke
Brief Summary: It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.


Options:
A: Arm Label: Dl-3-n-butylphthalide; Type: EXPERIMENTAL; Interventions: Drug: Dl-3-n-butylphthalide | Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dl-3-n-butylphthalide; Assigned to Arm(s): Dl-3-n-butylphthalide | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: NXY-059; Assigned to Arm(s): N/A
C: Arm Label: Study Group 1; Type: EXPERIMENTAL; Interventions: Drug: porcine brain peptide (Cerebrolysin) | Arm Label: Study Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: porcine brain peptide (Cerebrolysin); Assigned to Arm(s): Study Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Study Group 2
D: Arm Label: Cerebrolysin; Type: EXPERIMENTAL; Interventions: Drug: Cerebrolysin | Arm Label: 0.9% Saline Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.9% Saline Solution | Intervention Type: DRUG; Name: Cerebrolysin; Assigned to Arm(s): Cerebrolysin | Intervention Type: DRUG; Name: 0.9% Saline Solution; Assigned to Arm(s): 0.9% Saline Solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Breast Feeding and Iron: Comparison of Cereals Fortified With Different Forms of Iron
Brief Summary: The purpose of this research study is to determine whether the type of iron in infant cereals makes a differance in how well the cereal helps infants remain free of iron deficiency.


Options:
A: Arm Label: Cereal L; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: electrolytic iron | Arm Label: Cereal M; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: ferrous fumarate | Intervention Type: DIETARY_SUPPLEMENT; Name: electrolytic iron; Assigned to Arm(s): Cereal L | Intervention Type: DIETARY_SUPPLEMENT; Name: ferrous fumarate; Assigned to Arm(s): Cereal M
B: Arm Label: Standard well child care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food Activity Breast feeding support; Type: EXPERIMENTAL; Interventions: Behavioral: FAB | Arm Label: Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep | Arm Label: FAB + Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: FAB, Behavioral: Sleep | Intervention Type: BEHAVIORAL; Name: FAB; Assigned to Arm(s): FAB + Sleep, Food Activity Breast feeding support | Intervention Type: BEHAVIORAL; Name: Sleep; Assigned to Arm(s): FAB + Sleep, Sleep
C: Arm Label: Peanut Consumption Group; Type: EXPERIMENTAL; Interventions: Biological: Peanut Consumption Group | Arm Label: Peanut Avoidance Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Peanut Consumption Group; Assigned to Arm(s): Peanut Consumption Group
D: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo
Brief Summary: Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.


Options:
A: Arm Label: Immunotherapy; Type: EXPERIMENTAL; Interventions: Biological: Grass pollen allergens in a water/glycerol solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Grass pollen allergens in a water/glycerol solution; Assigned to Arm(s): Immunotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: SLIT; Type: EXPERIMENTAL; Interventions: Biological: sublingual immunotherapy | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: sublingual immunotherapy; Assigned to Arm(s): SLIT | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazax | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1, 2
D: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo
Brief Summary: Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazax | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Immunotherapy; Type: EXPERIMENTAL; Interventions: Biological: Grass pollen allergens in a water/glycerol solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Grass pollen allergens in a water/glycerol solution; Assigned to Arm(s): Immunotherapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adolescents Committed to Improvement of Nutrition and Physical Activity (ACTION)
Brief Summary: Community based participatory research principles will be used to create, implement and evaluate a culturally relevant and age-appropriate obesity intervention for adolescents who are overweight or obese. The intervention will be implemented through school-based health centers (SBHC) and will include clinical encounters with SBHC providers, use of Motivational Enhancement Therapy to help overweight/obese adolescents adopt healthier behaviors, and use of a community advisory council to develop obesity risk reduction strategies that will be delivered by print and digital video disc (DVD) media. To test efficacy of the ACTION intervention, overweight/obese adolescents will be recruited to either the intervention condition or the usual care condition. Students will have pre- and post- intervention measurements to assess if adolescents in the intervention condition will have improved risk factor profile for metabolic syndrome, improved nutrition and increased physical activity when compared with students in the usual care condition.


Options:
A: Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention - Web; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly access to interactive web site | Arm Label: Intervention - Group; Type: EXPERIMENTAL; Interventions: Behavioral: Group | Arm Label: Intervention - Cell Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Cell Phone | Intervention Type: BEHAVIORAL; Name: Cell Phone; Assigned to Arm(s): Intervention - Cell Phone | Intervention Type: BEHAVIORAL; Name: Weekly access to interactive web site; Assigned to Arm(s): Intervention - Web | Intervention Type: BEHAVIORAL; Name: Group; Assigned to Arm(s): Intervention - Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ACTION | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: ACTION; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): 2
C: Arm Label: Next.Step; Type: EXPERIMENTAL; Interventions: Other: Next.Step - e-therapeutic intervention program | Arm Label: Standard protocol; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard treatment protocol | Intervention Type: OTHER; Name: Next.Step - e-therapeutic intervention program; Assigned to Arm(s): Next.Step | Intervention Type: OTHER; Name: Standard treatment protocol; Assigned to Arm(s): Standard protocol
D: Arm Label: Glucomannan; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Glucomannan | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Glucomannan; Assigned to Arm(s): Glucomannan | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin

Answer: B